Methods And Compositions For The Treatment Of Gastrointestinal disorders
The use of chymotrypsin inhibitors for treating various disorders, including IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudoobstruction), and disorders and conditions associated with constipation is described.
1 . A method for increasing GC-C Receptor activity, the method comprising administering a composition comprising a chymotrypsin inhibitor.
2 - 3 . (canceled)
4 . A method for increasing intestinal motility, the method comprising administering a composition comprising a chymotrypsin inhibitor.
5 - 7 . (canceled)
8 . The method of claim 20 wherein the gastrointestinal disorder is selected from the group consisting of: constipation, a gastrointestinal motility disorder, irritable bowel syndrome, a functional gastrointestinal disorder, gastroesophageal reflux disease, functional heartburn, dyspepsia, functional dyspepsia, nonulcer dyspepsia, gastroparesis, chronic intestinal pseudo-obstruction, and colonic pseudo-obstruction.
9 - 11 . (canceled)
12 . The method of any of claim 1 further comprising administering guanylin or a biologically active variant or fragment thereof.
13 . A pharmaceutical composition comprising a chymotrypsin inhibitor and a pharmaceutically acceptable carrier.
14 . The composition of claim 10 further comprising guanylin or a biologically active variant or fragment thereof.
15 . The composition of claim 14 further comprising a GC-C Receptor agonist.
16 . The method of claim 1 further comprising administering a GC-C Receptor agonist.
17 . (canceled)
18 . The method of claim 1 wherein the disorder is congestive heart failure.
19 . The method of claim 1 wherein the disorder is prostatic hyperplasia.
20 . The method of claim 1 wherein the disorder is a gastrointestinal disorder.
21 . The method of claim 1 wherein the disorder is obesity.